StreetInsider.com News Articles

Intellia Therapeutics names new chief medical officer

Tue, 13 Oct 2026 07:30:30 -0400

Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026, according to a company press release.

Dr. Marantz brings more than 25 years of biopharmaceutical industry experience, with a background spanning research and development, medical affairs, business development, and portfolio strategy. In her new role, she will oversee Intellia's translational, development, regulatory, and medical affairs functions.

Most recently, Dr. Marantz served as Chief Medical Officer at Scholar Rock, where she led development efforts that resulted in the U.S. approval of ISEMBYLD, a muscle-targeted therapy for Spinal

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

Tue, 13 Oct 2026 07:30:00 -0400

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company’s translational, development, regulatory and

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

Tue, 13 Oct 2026 07:30:00 -0400

Form 4 Intellia Therapeutics, For: Oct 02 Filed by: Dube Michael P

Tue, 06 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261006/27155451.html

Barclays Starts Intellia Therapeutics (NTLA) at Underweight

Tue, 06 Oct 2026 06:11:46 -0400

Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ: NTLA) with a Underweight rating and a price target of $8.00.

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $12.75 yesterday.

Form 144 Intellia Therapeutics, Filed by: Clark Eliana

Mon, 05 Oct 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20261005/27149496.html

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on October 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 44,450 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)

Wed, 09 Sep 2026 07:29:23 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst commented: "Priority Review and AdCom absence shift lonvo-z’s remaining risk away from efficacy, in our view. Intellia indicated that the FDA has accepted the lonvo-z Biologics License Application (BLA) for review, granted Priority Review and set a March 10, 2027 approval decision date; the agency also advised Intellia that it is not planning an advisory committee (AdCom) meeting. HAELO randomized 80 patients ages 16+ and reduced mean monthly HAE attacks by 87% vs. placebo, with 62% of lonvo-z-treated patients attack-

Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens

Wed, 09 Sep 2026 04:26:21 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $30.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst commented, "Following positive data from the Phase 3 HAELO study of lonvo-z in hereditary angioedema (HAE) at EAACI in June, Intellia Therapeutics announced FDA acceptance of the BLA for lonvo-z with a priority review. The FDA has assigned NTLA's application a PDUFA action date of March 10, 2027, solidifying the timeline to potential approval of the first one-time therapy for HAE. We maintain our Market Outperform rating and $30 DCF-derived price target on Intellia Therapeutics."

For an analyst ratings summary and ratings

FDA accepts Intellia's lonvo-z application with priority review status

Tue, 08 Sep 2026 08:10:46 -0400

Intellia Therapeutics (Nasdaq: NTLA) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z, a CRISPR-based therapy for hereditary angioedema (HAE), and granted it Priority Review status.

The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027. The agency also advised Intellia that it does not currently plan to hold an advisory committee meeting to discuss the application.

If approved, Intellia claims lonvo-z would be the first in vivo CRISPR-based therapy and the only one-time treatment for HAE.

The BLA is supported by data from Intellia's Phase 3

FDA accepts Intellia's lonvo-z application with priority review status

Tue, 08 Sep 2026 08:10:46 -0400

If approved, Intellia claims lonvo-z would be the first in vivo CRISPR-based therapy and the only one-time treatment for HAE.

The BLA is supported by data from Intellia's Phase 3

Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens on HAE Opportunity

Tue, 08 Sep 2026 04:25:57 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $30.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst commented, "We view HAE as a significant opportunity for NTLA and believe the financing around lonvo-z highlights the potential. What keeps us interested and optimistic is the fast enrollment pace, feedback from KOLs (takeaways here), and comments by Dr. Marc Riedl regarding the experience at his center. Real differentiation is the one-and-done approach that delivers attack reductions without ongoing therapy. Even next-generation therapies (e.g., BW-20805, ADX-324) still require quarterly to semi-annual therapy and will likely have a portion of patients that

Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens Before ESC Congress

Tue, 25 Aug 2026 04:14:42 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $30.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst commented, " At the European Society of Cardiology (ESC) Congress 2026 later this week, AstraZeneca (AZN, NC) will present detailed results from the previously announced, failed Ph3 CARDIOTTRansform study evaluating the siRNA therapeutic Wainua (eplontersen) in ATTR-CM. In July, the company reported that eplontersen failed to meet the study's primary efficacy endpoint in a population where ~80% of patients were receiving background transthyretin stabilizer therapy. We expect the full data presentation to provide important insights into the challenges of demonstrating clinical

Form 4 Intellia Therapeutics, For: Aug 20 Filed by: LEONARD JOHN M

Mon, 24 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260824/26968093.html

Form 4 Intellia Therapeutics, For: Aug 20 Filed by: LEONARD JOHN M

Mon, 24 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260824/26968093.html

Form 144 Intellia Therapeutics, Filed by: LEONARD JOHN M

Thu, 20 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260820/26956109.html

Form 144 Intellia Therapeutics, Filed by: LEONARD JOHN M

Thu, 20 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260820/26956109.html

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 38,200 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

Form SCHEDULE 13G Intellia Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:55:00 -0400

si-local-file:///var/storage/secattach/20260807/26888710.html

Form SCHEDULE 13G Intellia Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:55:00 -0400

si-local-file:///var/storage/secattach/20260807/26888710.html

Evercore ISI Upgrades Intellia Therapeutics (NTLA) to Outperform

Thu, 06 Aug 2026 16:17:14 -0400

Evercore ISI analyst Jonathan Miller upgraded Intellia Therapeutics (NASDAQ: NTLA) from In Line to Outperform with a price target of $24.00 (from $16.00).

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $10.97 yesterday.